MYDECINE INNOVAT.GRP

MYDECINE INNOVAT.GRP

Share · CA62849F2008 (XTSE)
Overview
AI-Powered Analysis
Fundamental Analysis
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of MYDECINE INNOVAT.GRP
No Price
28.04.2026 20:00
Current Prices from MYDECINE INNOVAT.GRP
ExchangeTickerCurrencyLast TradePriceDaily Change
OTC: UTC
UTC
MYCOF
USD
28.04.2026 20:00
1,00 USD
0,00 USD
Company Profile for MYDECINE INNOVAT.GRP Share
Mydecine Innovations Group Inc., a biotech and life sciences company, engages in the development and commercialization of drugs for treating mental health problems. It develops therapies for veterans, emergency medical service providers, post-traumatic stress disorder, and front-line workers; and operates Mindleap, a digital telehealth platform that provides access to mental health services, as well as psychedelic integration services, including psychedelic aftercare and wellness services. The company also engages in the drug discovery and builds nature-sourced psychedelic-assisted therapeutics, compounds, therapy protocols, and unique delivery systems. In addition, it operates hemp farm in Pottus, Texas. Mydecine Innovations Group Inc. has a partnership with Leiden University Medical Center; Royal Ottawa Mental Health Centre; LeadGen Labs to support psychedelic drug development; and Applied Pharmaceutical Innovation for drug development and clinical trial programs. The company was formerly known as NewLeaf Brands Inc. and changed its name to Mydecine Innovations Group Inc. in June 2020. Mydecine Innovations Group Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

Company Data

Name MYDECINE INNOVAT.GRP
Company Mydecine Innovations Group Inc.
Website https://www.mydecine.com
Primary Exchange XTSE TSX
ISIN CA62849F2008
Asset Class Share
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
CEO David Joshua Bartch
Country Canada
Currency CAD
Employees 0,0 T
Address 789 West Pender Street, V6C 1H2 Vancouver
IPO Date 2021-01-08

Stock Splits

Date Split
21.10.2025 1:50
21.04.2022 1:50
01.04.2019 1:45

Ticker Symbols

Name Symbol
Over The Counter MYCOF
Frankfurt 0NF0.F
More Shares
Investors who hold MYDECINE INNOVAT.GRP also have the following shares in their portfolio:
ALPHA BANK 25/36 FLR MTN
ALPHA BANK 25/36 FLR MTN Bond
DT.BANK MTN 17/21 NK
DT.BANK MTN 17/21 NK Bond